Skip to main content
. 2020 Oct 16;4(6):1183–1190. doi: 10.1002/jgh3.12420

Figure 2.

Figure 2

Survival and radiological objective response assessed by the first and second evaluations with the RECIST 1.1, mRECIST, and Choi criteria. (a) Patients with objective response (OR, blue), stable disease (SD, green), and progressive disease (PD, red) in the first evaluation. The P‐values are from log‐rank tests. (b) Survival curve of patients grouped by the first and second mRECIST and Choi criteria evaluations. OR or SD in the first and second evaluations (blue), OR or SD in the first evaluation and PD in the second evaluation (green), and PD in the first and second evaluations (red). The P‐values are from log‐rank tests. (c) The 4‐week relative dose intensity (RDI) after the first radiological evaluation and the second radiological response classified as BCLC stages B and C.